OraSure Technologies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
OraSure Technologies şirketinin kazançları yıllık ortalama -9.5% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 10.1% oranında artan oldu. Gelirler yıllık ortalama 5.5% oranında azalan oldu.
Anahtar bilgiler
-9.55%
Kazanç büyüme oranı
-8.77%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 8.90% |
| Gelir büyüme oranı | -5.50% |
| Özkaynak getirisi | -20.17% |
| Net Marj | -59.76% |
| Sonraki Kazanç Güncellemesi | 06 May 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.
OSUR: Activist Campaign And Governance Changes Will Support Future Upside
Analysts have made a modest adjustment to their price target for OraSure Technologies to $4.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiple. What's in the News Altai Capital Management has escalated its campaign, calling for a broad review of options including a potential sale of OraSure Technologies, criticizing executive pay and board oversight, and urging shareholders to support its director nominees Rishi Bajaj and John Bertrand at the 2026 annual meeting (Investor Activism, March 18, 2026).OSUR: Activist Board Push And Buybacks Will Support Future Upside
Analysts have lifted their price target on OraSure Technologies to $4.00 from $3.00, citing updated expectations regarding revenue growth, profit margins, and a modestly higher future P/E multiple. What's in the News Altai Capital Management sent a letter to OraSure's board on March 17, 2026, outlining a five-pillar case for change, citing share price underperformance, board ownership levels, CEO pay structure, a call for a strategic review, and support for its nominees, Rishi Bajaj and John Bertrand, to join the board (Investor Activism) Altai Capital formally nominated Bajaj and Bertrand for election to the board at the 2026 Annual Meeting and submitted a proposal to declassify the board so all directors stand for annual elections (Investor Activism) OraSure issued first quarter 2026 guidance, projecting total revenues of US$26 million to US$29 million, with only a negligible contribution from COVID 19 testing (Corporate Guidance) The company reported completing a share repurchase of 5,245,180 shares, or 7.12% of its stock, for US$14.89 million under a buyback program announced on March 24, 2025, including 1,900,000 shares bought for US$5 million between October 1 and December 31, 2025 (Buyback Tranche Update) OraQuick HIV Self Test received a Health Canada license as the first oral HIV self test in Canada, offering 20 minute results from an oral swab and distribution through St. Michael's Hospital to support access across healthcare and community settings (Product Related Announcement) Valuation Changes Fair Value: The analyst fair value estimate has risen from $3.00 to $4.00 per share, which represents a material upward revision to the target level.OSUR: New STI Self Testing Submissions Will Drive Future Upside
Analysts have raised their price target on OraSure Technologies from $4.50 to $5.00, citing updated assumptions around revenue growth, profit margin and future P/E that they state better reflect the company’s current outlook. What's in the News OraSure completed a share repurchase tranche between October 1, 2025 and December 31, 2025, buying 1,900,000 shares, or 2.63% of shares, for US$5 million.OSUR: New STI Self Testing Submissions Will Support Future Shareholder Upside
Narrative Update on OraSure Technologies Analysts have kept their OraSure Technologies fair value estimate steady at $4.50, with only marginal tweaks to inputs like the discount rate, long term revenue growth, profit margin, and future P/E assumptions driving this maintained price target. What's in the News OraQuick HIV Self-Test received a Health Canada license, becoming Canada's first oral HIV self test and offering results in about 20 minutes from an oral swab for HIV 1 and HIV 2 antibodies.OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
Analysts have modestly revised their price target for OraSure Technologies to US$4.50, reflecting slightly adjusted assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes leave their overall view of the company’s fair value essentially unchanged.OSUR: At-Home STI Testing Pipeline Will Drive Future Upside
Analysts have maintained their price target on OraSure Technologies at US$3.00. This reflects updated views on factors such as discount rate, revenue growth assumptions, profit margins, and future P/E expectations, while keeping the headline valuation level unchanged.OSUR: At-Home STI Testing And Activist Push Will Drive Future Upside
Analysts have kept their fair value estimate for OraSure Technologies steady at US$3.00 per share, citing largely unchanged assumptions around the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What's in the News OraSure submitted two applications to the U.S. FDA at the end of 2025 for clearance of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections, both aimed at over-the-counter and at-home use (Key Developments).OSUR: Activist Board Challenge Will Drive Future Shareholder Value Upside
Analysts have reduced their price target on OraSure Technologies from 5.00 dollars to 3.00 dollars per share, citing a higher required return on equity and lower expected future valuation multiples, despite improving revenue growth assumptions and largely stable profit margins. What's in the News Altai Capital Management notified OraSure Technologies Board on December 17, 2025 of its intention to nominate two directors at the 2026 annual meeting, citing share price underperformance and capital allocation concerns (Key Developments).OSUR: Ongoing Share Repurchases Will Drive Future Shareholder Value
Analysts have raised their price target on OraSure Technologies from 4.50 dollars to 4.75 dollars, citing slightly lower discount rate assumptions and a modestly higher long term valuation multiple, despite a small reduction in projected profit margins. What's in the News Completed a share repurchase of 3,345,180 shares, representing 4.49% of outstanding shares, for a total of $9.89 million under the buyback program announced on March 24, 2025 (Key Developments) From July 1, 2025 to September 30, 2025, repurchased 1,524,424 shares, or 2.07% of outstanding shares, for $4.9 million as the latest tranche of the ongoing buyback (Key Developments) Issued fourth quarter 2025 earnings guidance, projecting total revenues of $25 million to $28 million (Key Developments) Q4 2025 outlook includes less than $100,000 in COVID-19 testing revenue, underscoring the company’s pivot away from pandemic-driven sales (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 4.50 dollars per share, indicating no revision to the intrinsic value assessment.OSUR: Share Buybacks And Board Actions Will Drive Shareholder Value
Narrative Update: Analyst Price Target Adjustment for OraSure Technologies Analysts have reduced OraSure Technologies’ price target from $4.75 to $4.50, citing updated assumptions in growth and profitability metrics. What's in the News OraSure Technologies repurchased 1,524,424 shares for $4.9 million during Q3 2025, completing a total buyback of 3,345,180 shares under the repurchase plan announced in March 2025 (Key Developments).Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive
Nov 14
OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 08OraSure Technologies: An Asymmetric Bet
Jul 28Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
May 08Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
Feb 27
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Dec 11Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Nov 14Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
Nov 08OraSure: An NCAV Diamond In The COVID Rough
Nov 04OraSure Technologies: Nursing A COVID-19 Hangover
Sep 10OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
May 11Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
Apr 17Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Mar 01Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
Feb 29OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
Dec 20Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled
Nov 08Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
OraSure Technologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 115 | -69 | 73 | 43 |
| 30 Sep 25 | 126 | -60 | 76 | 37 |
| 30 Jun 25 | 139 | -51 | 76 | 33 |
| 31 Mar 25 | 162 | -32 | 77 | 27 |
| 31 Dec 24 | 186 | -19 | 75 | 25 |
| 30 Sep 24 | 224 | 11 | 78 | 26 |
| 30 Jun 24 | 274 | 27 | 79 | 29 |
| 31 Mar 24 | 305 | 23 | 84 | 31 |
| 31 Dec 23 | 405 | 54 | 92 | 33 |
| 30 Sep 23 | 453 | 49 | 99 | 34 |
| 30 Jun 23 | 480 | 44 | 109 | 36 |
| 31 Mar 23 | 475 | 30 | 113 | 38 |
| 31 Dec 22 | 387 | -17 | 117 | 36 |
| 30 Sep 22 | 328 | -43 | 118 | 37 |
| 30 Jun 22 | 265 | -64 | 115 | 36 |
| 31 Mar 22 | 243 | -47 | 107 | 34 |
| 31 Dec 21 | 234 | -23 | 95 | 34 |
| 30 Sep 21 | 233 | -11 | 89 | 36 |
| 30 Jun 21 | 227 | 5 | 80 | 35 |
| 31 Mar 21 | 199 | -4 | 79 | 34 |
| 31 Dec 20 | 172 | -15 | 77 | 31 |
| 30 Sep 20 | 158 | -14 | 74 | 27 |
| 30 Jun 20 | 146 | -2 | 72 | 23 |
| 31 Mar 20 | 156 | 13 | 67 | 21 |
| 31 Dec 19 | 155 | 17 | 65 | 20 |
| 30 Sep 19 | 150 | 25 | 73 | 18 |
| 30 Jun 19 | 159 | 20 | 70 | 17 |
| 31 Mar 19 | 161 | 19 | 69 | 17 |
| 31 Dec 18 | 182 | 20 | 69 | 16 |
| 30 Sep 18 | 177 | 17 | 57 | 16 |
| 30 Jun 18 | 174 | 15 | 57 | 15 |
| 31 Mar 18 | 174 | 16 | 58 | 14 |
| 31 Dec 17 | 166 | 31 | 58 | 13 |
| 30 Sep 17 | 145 | 31 | 60 | 10 |
| 30 Jun 17 | 135 | 31 | 59 | 10 |
| 31 Mar 17 | 126 | 30 | 57 | 10 |
| 31 Dec 16 | 123 | 20 | 58 | 10 |
| 30 Sep 16 | 125 | 17 | 58 | 11 |
| 30 Jun 16 | 123 | 12 | 61 | 10 |
| 31 Mar 16 | 122 | 11 | 62 | 10 |
| 31 Dec 15 | 120 | 8 | 61 | 11 |
| 30 Sep 15 | 116 | 1 | 63 | 12 |
| 30 Jun 15 | 114 | 1 | 61 | 13 |
Kaliteli Kazançlar: OSUR şu anda kârlı değil.
Büyüyen Kar Marjı: OSUR şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: OSUR kârlı değildir ve zararlar son 5 yılda yılda 9.5% oranında artmıştır.
Büyüme Hızlandırma: OSUR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: OSUR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 7.5% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: OSUR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -20.17% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/04/30 03:12 |
| Gün Sonu Hisse Fiyatı | 2026/04/30 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
OraSure Technologies, Inc. 15 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |